Key result
Among 2,188 patients with spinal muscular atrophy, 60.4% received at least one disease-modifying treatment, though high missingness of functional data in untreated patients limited evaluation of treatment-related changes.
Why the study?
Since the approval of new disease-modifying treatments, studies have reported changes in spinal muscular atrophy disease progression.
Does treatment with disease-modifying therapies improve functional status and motor milestones in patients with 5q spinal muscular atrophy compared to untreated patients?
Cohort (n=2,188)
Yes
Does treatment with disease-modifying therapies improve functional status and motor milestones in patients with 5q spinal muscular atrophy compared to untreated patients?
Real-world European registry data demonstrates functional milestones achieved by SMA patients on disease-modifying therapies, though high data missingness limits robust comparisons with untreated cohorts.
Answers are grounded in this paper and cite their sources.
DMT exposure was associated with altered SMA progression; leaves open comparative effectiveness and durability across therapies in broader populations.
Background Spinal muscular atrophy (SMA), a rare neurodegenerative disorder with an estimated prevalence of 1 in 14,300 live births and is the leading genetic cause of mortality in infants and children. Since the approval of new disease-modifying treatments (DMTs; nusinersen (Spinraza) in 2017, onasemnogene abeparvovec-xioi (Zolgensma) in 2020, and oral risdiplam (Evrysdi) in 2021), studies have reported changes in disease progression. This retrospective cohort study analyzed six SMA registries within the TREAT-NMD network, selected via feasibility assessment. These registries comprise data from nine European countries: three clinician-based registries (Belgium, Czech Republic plus Slovakia, Sweden) and three patient-based registries (Germany plus Austria, Spain, United Kingdom plus Ireland) covering the period spanning April 2008 and May 2023. Results Among 2,188 SMA patients with genetically confirmed 5q SMA, the most common SMA subtype was type 2 (SMA2; n = 914, 41.8%) followed by types 3 (SMA3; n = 779, 35.6%) and 1 (SMA1; n = 432, 19.7%). Treatment with at least one DMT was reported among 1,321 (60.4%) of patients and increased over time; nusinersen was the most common DMT ( N = 1,003; 75.9%) followed by risdiplam ( N = 403; 30.5%) and onasemnogene ( N = 101; 7.6%). Among treated patients with SMA1, SMA2, and SMA3, best functional status reported was “sitter” for 36.6%, 60.9%, and 5.3%, and “walker” for 12.0%, 24.6%, and 87.8%, respectively. For SMA1 and SMA2, best motor milestone reported was “sit without support” for 27.2% and 38.0%, and “roll onto side” for 18.5% and 2.0%; for SMA3, “climb stairs” was reported for 63.4% and “walk 10 metres without assistance” reported for 19.3%. Missingness of functional status and motor milestone among patients with SMA1, SMA2, and SMA3 was lower among those treated (27.9%, 8.5%, and 5.5%) as accounted for almost all never treated (100%, 97.8%, and 100%). Conclusions Functional status and motor milestones were well captured after treatment but rarely reported before treatment or in patients who were never treated, limiting evaluation of treatment related changes. Areas of improvement for registry data quality have been identified to reduce data missingness, increase standardisation, and consequently enhance their ability to inform regulatory decision making.
No takes yet. Share an insight, caveat, or question.
Deltour et al. (2026) conducted a cohort in Spinal muscular atrophy (SMA) (n=2,188). Disease-modifying treatments (nusinersen, risdiplam, onasemnogene abeparvovec) vs. Never treated was evaluated on Best functional status and motor milestone. Among 2,188 patients with spinal muscular atrophy, 60.4% received at least one disease-modifying treatment, though high missingness of functional data in untreated patients limited evaluation of treatment-related changes.
Synapse has enriched 10 related papers. Consider them for comparative context: